Xilio Therapeutics Inc. (XLO)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
1.07
-0.01 (-0.93%)
At close: Jan 15, 2025, 10:23 AM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 |
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 1.90M | 1.85M | 1.50M | 1.06M | 240.00K |
Gross Profit | -1.90M | -1.85M | -1.50M | -1.06M | -240.00K |
Operating Income | -79.13M | -89.15M | -75.04M | -54.56M | -19.03M |
Interest Income | n/a | n/a | 600.00 | 600.00 | n/a |
Pretax Income | -76.40M | -88.22M | -75.80M | -55.22M | -17.31M |
Net Income | -76.40M | -87.30M | -74.30M | -55.22M | -17.31M |
Selling & General & Admin | 27.00M | 29.95M | 23.86M | 10.65M | 4.77M |
Research & Development | 52.14M | 59.20M | 51.19M | 43.91M | 14.26M |
Other Expenses | n/a | 927.00K | -756.00K | -656.00K | 1.72M |
Operating Expenses | 79.13M | 89.15M | 75.04M | 54.56M | 19.03M |
Interest Expense | n/a | n/a | 600.00K | 600.00K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 79.13M | 89.15M | 75.04M | 54.56M | 19.03M |
Income Tax | n/a | -927.00K | -1.50M | 858.70K | 68.14K |
Shares Outstanding (Basic) | 27.50M | 27.39M | 27.36M | 27.47M | 27.47B |
Shares Outstanding (Diluted) | 27.50M | 27.39M | 27.36M | 27.47M | 27.47B |
EPS (Basic) | -2.78 | -3.19 | -2.72 | -2.01 | -0.00 |
EPS (Diluted) | -2.78 | -3.19 | -2.72 | -2.01 | -0.00 |
EBITDA | -73.80M | -85.58M | -73.70M | -53.50M | -17.07M |
Depreciation & Amortization | 1.90M | 1.85M | 1.50M | 1.06M | 240.00K |